Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Swedish Orphan Biovitrum AB.

Community Practice Connection™ Primary HLH: Diagnosis, Management, and Treatment in the 21st Century

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

Hemophagocytic lymphohistiocytosis (HLH) is a rare blood disorder mediated by overactivated immune cells. Rare hematologic disorders present a distinct challenge for hematologists and other physicians, and prompt differential diagnosis and initiation of effective treatment are critical to optimizing outcomes for patients with HLH. This online program will provide physicians who encounter these patients with up-to-date information on the diagnosis, pathobiology, and treatment of primary HLH. Through a series of short video interviews, the expert faculty will review and contextualize the latest clinical data and ongoing clinical trials with the potential to impact care of patients with HLH. Interactive case studies with expert perspective on steps in diagnosis and treatment will provide the opportunity to apply new information to clinical scenarios, equipping participants to utilize emerging data in the optimal care of their patients with HLH.

Benefits of Participating

This activity will better prepare you to:

  • Gain an understanding of cutting-edge data regarding optimal treatment strategies for patients with HLH.
  • Hear expert perspectives on how to integrate current and emerging agents into clinical practice.
  • Challenge your treatment decision making for patients with HLH through interactive expert review of patient case studies.
  • Learn about clinically relevant advances in the understanding of HLH pathobiology.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Swedish Orphan Biovitrum AB.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other healthcare professionals interested in the latest advances in the treatment of patients with HLH. Fellows, researchers, nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Identify key diagnostic criteria and strategies for the differential diagnosis of HLH.
  • Evaluate clinical trial data regarding safety and efficacy for emerging therapies and treatment strategies for HLH in the frontline and later-line settings.
  • Integrate emerging options for treatment of patients with HLH into the real-world clinical setting.

Faculty, Staff, and Planners’ Disclosures

Faculty

Michelle L. Hermiston
Michelle L. Hermiston, MD, PhD
Associate Professor
Department of Pediatrics
UCSF School of Medicine
Pediatric Hematologist and Oncologist
Benioff Children’s Hospital
University of California, San Francisco
San Francisco, CA

Disclosures: no relevant financial relationships with commercial interests.

Ashish R. Kumar
Ashish R. Kumar, MD, PhD
Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Director, Langerhans Cell Histiocytosis Center
Director, Hematology/Oncology Fellowship Program
Cincinnati Children’s Hospital Medical Center
University of Cincinnati College of Medicine
Cincinnati, OH

Disclosures: Consultant: Swedish Orphan Biovitrum AB; Speakers Bureau: Swedish Orphan Biovitrum AB.

Kenneth L. McClain
Kenneth L. McClain, MD, PhD
Professor, Department of Pediatrics, Section of Hematology/Oncology
Baylor College of Medicine
Director, Histiocytosis Program
Director, Pediatric Lymphoma–Histiocytosis Fellowship Program
Texas Children’s Hospital
Houston, TX

Disclosures: no relevant financial relationships with commercial interests.

Philip A. Roehrs
Philip A. Roehrs, MD
Associate Professor
Medical Director, Pediatric Transplant and Cellular Therapies Program
Levine Children’s Hospital
Carolinas Medical Center
Charlotte, NC

Disclosures: Speakers Bureau: Swedish Orphan Biovitrum AB; Other: Investigational/Off Label: etoposide, alemtuzumab.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
31
Filter By